Capsule Summary Slidesets

Share

Program Content

Activities

  • KEYNOTE-054 Recurrence
    KEYNOTE-054: Analysis of Crossover and Rechallenge With Pembrolizumab in Recurrent Patients After Complete Resection of High-Risk Stage III Melanoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2021

    Expires: June 09, 2022

  • Neoadjuvant RELA + NIVO
    Phase II Trial of Dual LAG-3–PD-1 Inhibition With Neoadjuvant Relatlimab + Nivolumab in Resectable Stage III Melanoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2021

    Expires: June 06, 2022

  • RELATIVITY-047
    RELATIVITY-047: Phase II/III Trial of First-line Relatlimab + Nivolumab vs Nivolumab Alone in Advanced Melanoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2021

    Expires: June 06, 2022

  • LEAP-004 Update
    LEAP-004 Update: Lenvatinib Plus Pembrolizumab for Advanced Melanoma Following Progression on a PD-1/PD-L1 Inhibitor
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2021

    Expires: June 08, 2022

  • Lifileucel in Adv Melanoma
    Update From a Global Phase II Study of Lifileucel, an Autologous TIL Therapy, in Patients With Previously Treated Advanced Melanoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2021

    Expires: June 07, 2022

  • CheckMate 067 6.5-Yr Update
    CheckMate 067 6.5-Yr Follow-up: Long-term Safety and Efficacy of Nivolumab and Ipilimumab for First-line Treatment of Advanced Melanoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2021

    Expires: June 07, 2022

  • COLUMBUS 5-Yr Update
    COLUMBUS: 5-Yr OS With Encorafenib + Binimetinib in BRAF V600–Mutant Melanoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2021

    Expires: June 09, 2022

  • ABC: Nivo/Ipi for Brain Mets
    ABC Study: 5-Yr Survival Outcomes With Nivolumab ± Ipilimumab in Patients With Melanoma Brain Metastases
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2021

    Expires: June 09, 2022

  • CheckMate 511 NIVO/IPI Dosing
    CheckMate 511: 3-Year Follow-up of 2 Different Dosing Regimens of Nivolumab + Ipilimumab for Patients With Advanced Melanoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2021

    Expires: June 05, 2022

Provided by

ProCE Banner

Supporters

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme